What does stem cell therapy cost from start to finish?

What belongs in the written price?

The quote needs to name what will be put into your joint. It also needs to list every service you're buying.

Image guidance means watching an ultrasound screen while placing the treatment. Ask whether that help, later visits, a brace, and medicines are included.

Read the rules for deposits, refunds, repeat care, and cancelled visits before signing. If the wording isn't clear, ask for a new written total.

Will insurance pay any of it?

Many plans don't cover these cash-pay treatments, so check with your insurer yourself. Use the exact service and billing details from the office.

Some exams, braces, medicines, and physical therapy may be covered. Your bill depends on your plan, whether the office works with your insurer, and the service being billed.

A payment plan isn't insurance and doesn't lower the full price. It only spreads out when you pay what is owed.

What else can cost me money?

Count gas, missed work, help at home, and limits after treatment. A short office visit can still upset several days of your routine.

Waiting too long to ask about surgery can also cost you. That matters when you're sore at rest and can barely use the joint.

Now weigh the money, likely relief, recovery, and unknowns together. A high price isn't proof that care will work better.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

3. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

4. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

5. An analysis of 38 businesses advertising stem cell and exosome products for COVID-19 found listed prices from $2,950 to $25,000 with an average of $11,322 - a direct measure of what this marketplace charges for products with no regulatory approval.

   Turner L, et al. — Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims. Stem Cell Reports, 2023. DOI: 10.1016/j.stemcr.2023.09.015.

6. A systematic review of 21 studies re-examining the familiar '20 percent are dissatisfied after knee replacement' figure found the actual average dissatisfaction rate was 10 percent, and 7.3 percent when complications were excluded - the surgical benchmark a cash-pay injection is implicitly competing against.

   DeFrance MJ, et al. — Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature. J Arthroplasty, 2023. DOI: 10.1016/j.arth.2022.10.011.